Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) utilizes angiotensin-
converting enzyme 2 (ACE2) as its main receptor for cell entry. We bioengineered a soluble …

Background Antibody-mediated immune responses play a crucial role in the immune
defense of human body. The evolution of bioengineering has led the progress of antibody …

Abstract Nirmatrelvir/ritonavir (N/R) is one of the most effective antiviral drugs against SARS-
CoV-2. The preclinical development, pharmacodynamics and pharmacokinetics of N/R are …

Introduction The COVID-19 pandemic is a major global public health crisis. More than 2
years into the pandemic, effective therapeutic options remain limited due to rapid viral …

Antibody therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have been
approved in many countries, with most being developed based on the original strain of …

Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro …

Monoclonal antibodies are an increasingly important tool for prophylaxis and treatment of
acute virus infections like SARS-CoV-2 infection. However, their use is often restricted due to …

Multiple randomized, controlled clinical trials have yielded discordant results regarding the
efficacy of convalescent plasma in outpatients, with some showing an approximately 2-fold …

Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for
prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in …

For decades, immunoglobulin preparations have been used to prevent or treat infectious
diseases. Since only a few years, monoclonal antibody applications (mAbs) are taking flight …